Home > Search Clinical Trials > Bacterial and Fungal
Clinical Trials: Bacterial and Fungal
IRB No. 12-009-2 (Dr. Mark Metersky, PI): Bronchiectasis Research Registry: A Consolidated Database of Non-Cystic Fibrosis Bronchiectasis Patients from Major Clinical and Research Institutions
Study description not available
IRB No. 16-170J-1 (Dr. Thomas Devers, PI): Microbiome analysis in C. Difficile Infection and Fecal Microbiota Transplant
Clostridium difficile is a bacteria which causes life-threatening inflammation of the colon, infection and diarrhea. C. difficile infection (CDI) is difficult to treat and is associated with a high rate of antibiotic failure. Recurrence of CDI is common and occurs in 30 - 65% of patients. The recent development of Fecal Microbiota Transplant (FMT) stool transplant therapy, that involves the infusion of stool from a healthy donor into the infected colon, has demonstrated effectiveness in curing CDI. This research study will involve close collaboration between gastroenterologists at UConn Health and Microbial Genomics at the Jackson Laboratory for Genomic Medicine (JAX-GM). The specific aims of this project include identification and analysis of specific gut bacteria using genomic microbial analysis techniques in patients with C. Difficile infection pre- and post- stool transplant and of the healthy stool transplant donor. Through these analyses, we will gain a better understanding of the changes to the intestinal bacterial communities in Clostridium Difficile infection before and after FMT. This research may eventually lead to novel therapies by identification and isolation of intestinal bacteria associated with both infection and cure of CDI.
IRB No. 18-000-3.2 (Dr. Adam Lindsay, PI): Antibiotic Regimens in Patients Undergoing Tumor Resections with Endoprosthetic Replacements.
This study is a multi-center, blinded, randomized controlled trial, using a parallel two-arm design to investigate whether long term postoperative antibiotic regimens (5 days) will decrease the rate of infection among patients being surgically treated for a lower extremity bone tumor, when compared to short term postoperative antibiotics (24 hours). We will assess infection rates within 12 months after initial surgery across both study arms. We will measure function and quality of life preoperatively, and at 3 months, 6 months, and 1 year postoperatively.